
Keywords: MG; myasthenia gravis; AChR; acetylcholine receptor; MuSK; muscle specific kinase; EAMG; experimentally acquired myasthenia gravis; PTMG; passive transfer myasthenia gravis; Myasthenia gravis; Clinical trials; Therapeutic development; Preclinical assessme